Article ; Online: Emerging cases of mucormycosis under COVID-19 pandemic in India: Misuse of antibiotics.
2021 Volume 82, Issue 7, Page(s) 880–882
Abstract: ... in India during the second wave of COVID-19 than during the first wave, with at least 14,872 cases ... Therefore, the use of glucocorticoids or high doses of glucocorticoids in mild COVID-19 cases (without hypoxemia ... COVID-19's second wave had a significant impact on India, on May 7, 2021, the largest daily ...
| Abstract | COVID-19's second wave had a significant impact on India, on May 7, 2021, the largest daily recorded case count was a little more than 4 million, and it has since fallen. Although the number of new cases reported has dropped, during the third week of May 2021, India accounted for about 45% of new cases identified globally and around 34% of deaths. As India maintains its present level of stability, a new urgent threat has emerged in the form of coronavirus-associated mucormycosis. Mucormycosis, an acute and deadly fungal infection caused by Mucorales-related fungal species, is a fungal emergency with a particularly aggressive propensity for contiguous spread, associated with a poor prognosis if not properly and immediately identified, and treated. Mucormycosis, sometimes referred to as the "black fungus," has increased more rapidly in India during the second wave of COVID-19 than during the first wave, with at least 14,872 cases as of May 28, 2021. Uncontrolled diabetic mellitus (DM) and other immunosuppressive diseases such as neutropenia and corticosteroid treatment have traditionally been identified as risk factors for mucormycosis. Therefore, the use of glucocorticoids or high doses of glucocorticoids in mild COVID-19 cases (without hypoxemia) should be avoided. In addition, drugs that target the immune pathway, such as tocilizumab, are not recommended without clear benefits. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Anti-Bacterial Agents/adverse effects ; Anti-Bacterial Agents/therapeutic use ; COVID-19/complications ; COVID-19/drug therapy ; Emergency Medical Services ; Glucocorticoids/adverse effects ; Glucocorticoids/therapeutic use ; Humans ; India ; Mucormycosis/epidemiology ; Mucormycosis/etiology ; Pandemics ; Prescription Drug Misuse ; Prognosis ; Risk Factors | |||||
| Chemical Substances | Anti-Bacterial Agents ; Glucocorticoids | |||||
| Language | English | |||||
| Publishing date | 2021-07-29 | |||||
| Publishing country | United States | |||||
| Document type | Journal Article ; Observational Study | |||||
| ZDB-ID | 604587-x | |||||
| ISSN | 1098-2299 ; 0272-4391 | |||||
| ISSN (online) | 1098-2299 | |||||
| ISSN | 0272-4391 | |||||
| DOI | 10.1002/ddr.21862 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 2542: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.